Literature DB >> 16551497

Programmable implants--from pulsatile to controlled release.

C Guse1, S Koennings, T Blunk, J Siepmann, A Goepferich.   

Abstract

The aim of this study was to develop programmable implants with a reproducible delayed onset of release followed by several weeks of controlled release. For this purpose, a drug-loaded core was embedded into a drug-free bulk-eroding poly(D,L lactic-co-glycolic acid) or poly(D,L lactic acid) mantle. The manufacturing procedure was established and optimized for three mantle materials, which showed delay times ranging from 7 to 83 days. Triglycerides with fatty acid chain lengths from C12 to C18 were investigated as core materials, producing release periods from 2 to 16 weeks. Concomitantly, applying a convolution/deconvolution model showed the possibility of theoretical prediction of the resulting release profiles.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16551497     DOI: 10.1016/j.ijpharm.2005.12.051

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  2 in total

1.  Functionalized hydrophobic poly(glycerol-co-ε-caprolactone) depots for controlled drug release.

Authors:  Jesse B Wolinsky; Stefan T Yohe; Yolonda L Colson; Mark W Grinstaff
Journal:  Biomacromolecules       Date:  2012-02-01       Impact factor: 6.988

2.  Ovalbumin-containing core-shell implants suitable to obtain a delayed IgG1 antibody response in support of a biphasic pulsatile release profile in mice.

Authors:  Katie Amssoms; Philip A Born; Max Beugeling; Ben De Clerck; Ellen Van Gulck; Wouter L J Hinrichs; Henderik W Frijlink; Niels Grasmeijer; Guenter Kraus; Roger Sutmuller; Kenny Simmen; Lieven Baert
Journal:  PLoS One       Date:  2018-08-30       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.